219 related articles for article (PubMed ID: 34588580)
1. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway.
Liu H; Liu C; Wang M; Sun D; Zhu P; Zhang P; Tan X; Shi G
Sci Rep; 2021 Sep; 11(1):19268. PubMed ID: 34588580
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo.
Su CC; Chiu TL
Oncol Rep; 2016 Aug; 36(2):1173-9. PubMed ID: 27277844
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.
Wang L; Wu J; Lu J; Ma R; Sun D; Tang J
Mol Med Rep; 2015 Feb; 11(2):931-9. PubMed ID: 25355053
[TBL] [Abstract][Full Text] [Related]
6. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells.
Jiang Y; Bi Y; Zhou L; Zheng S; Jian T; Chen J
BMC Complement Med Ther; 2024 Jan; 24(1):68. PubMed ID: 38297301
[TBL] [Abstract][Full Text] [Related]
7. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
Acharya B; Chaijaroenkul W; Na-Bangchang K
J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Ding L; Ding L; Wang S; Wang S; Wang W; Wang W; Lv P; Lv P; Zhao D; Zhao D; Chen F; Chen F; Meng T; Meng T; Dong L; Dong L; Qi L; Qi L
Pharmacology; 2017; 99(3-4):188-195. PubMed ID: 27889779
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
10. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
Lv C; Zeng HW; Wang JX; Yuan X; Zhang C; Fang T; Yang PM; Wu T; Zhou YD; Nagle DG; Zhang WD
Cell Death Dis; 2018 Feb; 9(2):165. PubMed ID: 29416003
[TBL] [Abstract][Full Text] [Related]
11. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway.
Li Q; Shen L; Wang Z; Jiang HP; Liu LX
Biomed Pharmacother; 2016 Dec; 84():106-114. PubMed ID: 27643552
[TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
Ke F; Wang Z; Song X; Ma Q; Hu Y; Jiang L; Zhang Y; Liu Y; Zhang Y; Gong W
Drug Des Devel Ther; 2017; 11():1753-1766. PubMed ID: 28670110
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis.
Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
Int Immunopharmacol; 2019 Dec; 77():105968. PubMed ID: 31704290
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer.
Liu J; Zhang C; Liu S; Wang X; Wu X; Hao J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):365-374. PubMed ID: 36374307
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA alleviates acute ethanol-induced myocardial apoptosis mainly through inhibiting the expression of PDCD4 and activating the PI3K/Akt pathway.
Deng H; Yu B; Li Y
Phytother Res; 2021 Aug; 35(8):4309-4323. PubMed ID: 34169595
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway.
Won SH; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Jung DB; Shin JM; Kwon TR; Yun SM; Lee MH; Choi SH; Lü J; Kim SH
Biol Pharm Bull; 2010; 33(11):1828-34. PubMed ID: 21048307
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]